EA201891621A1 - INHIBITION OF ATAXIA-TELEEGIEGASTASIA AND RAD3-RELATED PROTEIN (ATR) - Google Patents

INHIBITION OF ATAXIA-TELEEGIEGASTASIA AND RAD3-RELATED PROTEIN (ATR)

Info

Publication number
EA201891621A1
EA201891621A1 EA201891621A EA201891621A EA201891621A1 EA 201891621 A1 EA201891621 A1 EA 201891621A1 EA 201891621 A EA201891621 A EA 201891621A EA 201891621 A EA201891621 A EA 201891621A EA 201891621 A1 EA201891621 A1 EA 201891621A1
Authority
EA
Eurasian Patent Office
Prior art keywords
atr
teleegiegastasia
rad3
ataxia
inhibition
Prior art date
Application number
EA201891621A
Other languages
Russian (ru)
Other versions
EA039513B1 (en
Inventor
Дэрил С. Драммонд
Болинь Гэн
Дмитри Б. Кирпотин
Суреш К. Типпараджу
Александер Кошкарёв
Озан Алкан
Original Assignee
Мерримак Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерримак Фармасьютикалз, Инк. filed Critical Мерримак Фармасьютикалз, Инк.
Priority claimed from PCT/US2017/012939 external-priority patent/WO2017123588A1/en
Publication of EA201891621A1 publication Critical patent/EA201891621A1/en
Publication of EA039513B1 publication Critical patent/EA039513B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Новые соединения, ингибирующие протеинкиназу ATR, включают соединения формулы (I), описанные в данном документе, а также липосомные составы, содержащие соединения-ингибиторы протеинкиназы ATR. Данные композиции пригодны для лечения рака.New compounds inhibiting protein kinase ATR include compounds of formula (I) described in this document, as well as liposomal formulations containing compounds inhibiting protein kinase ATR. These compositions are suitable for the treatment of cancer.

EA201891621A 2017-01-09 2017-01-11 INHIBITOR OF ATAXIA-TELANGIECTASIA AND Rad3-RELATED PROTEIN (ATR) AND LIPOSOME COMPOSITIONS COMPRISING SAME EA039513B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444172P 2017-01-09 2017-01-09
PCT/US2017/012939 WO2017123588A1 (en) 2016-01-11 2017-01-11 Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Publications (2)

Publication Number Publication Date
EA201891621A1 true EA201891621A1 (en) 2018-12-28
EA039513B1 EA039513B1 (en) 2022-02-04

Family

ID=80736183

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891621A EA039513B1 (en) 2017-01-09 2017-01-11 INHIBITOR OF ATAXIA-TELANGIECTASIA AND Rad3-RELATED PROTEIN (ATR) AND LIPOSOME COMPOSITIONS COMPRISING SAME

Country Status (1)

Country Link
EA (1) EA039513B1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172248A1 (en) * 2008-12-19 2011-07-28 Vertex Pharma Pyrazine derivatives useful as inhibitors of atr kinase
EP3878851A1 (en) * 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of atr kinase
CN103957917A (en) * 2011-09-30 2014-07-30 沃泰克斯药物股份有限公司 Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
EP2904406B1 (en) * 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
WO2015195740A1 (en) * 2014-06-17 2015-12-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US20170151339A1 (en) * 2014-06-30 2017-06-01 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
EA039513B1 (en) 2022-02-04

Similar Documents

Publication Publication Date Title
EA201892229A1 (en) SUBSTITUTED AMINOPURIN COMPOUNDS CONTAINING THEIR COMPOSITIONS AND TREATMENT METHODS WITH THEIR APPLICATION
PH12021500014A1 (en) Fused ring compounds
EA201891494A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201990221A1 (en) 1,3-DIHYDROXIPHENYL DERIVATIVES APPLICABLE AS IMMUNOMODULATORS
PH12017501888A1 (en) Bromodomain inhibitor
EA201790492A1 (en) CONNECTIONS THAT INHIBIT McL-1 PROTEIN
EA201890857A1 (en) COMPOUNDS APPLICABLE AS IMMUNOMODULATORS
EA201891203A1 (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201591145A1 (en) Inhibitors of histonedehylase
EA201692513A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201890247A1 (en) DEZOXYURIDINTRIPHIPHPHATASI INHIBITORS CONTAINING HYDANTOIN
EA201592068A1 (en) INHANSER INHIBITORS ZESTE HOMOLOGIST 2
EA201891526A3 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA202090497A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF HEMATOLOGICAL DISORDERS
EA201591781A1 (en) CHEMICAL COMPOUNDS
EA201692470A1 (en) PHARMACEUTICAL COMBINATIONS
EA202191476A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201790603A1 (en) Inhibitors of histonedehylase
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
MY201291A (en) Aminothiazole compounds as protein kinase inhibitors
MX2018008507A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr).